Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer

We designed and synthesized novel AR pure antagonists for the treatment of castration-resistant prostate cancer. CH5137291 was a potent AR pure antagonist without formation of agonist metabolite.